AVH — AVITA Medical Cashflow Statement
0.000.00%
- AU$160.19m
- AU$196.21m
- $71.61m
Annual cashflow statement for AVITA Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.6 | -26.7 | -35.4 | -61.8 | -48.6 |
| Depreciation | |||||
| Non-Cash Items | 7.32 | 8.2 | 3.31 | 16.5 | 11.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.36 | -1.2 | -6.57 | -4.68 | 3.44 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.9 | -19.1 | -38 | -48.9 | -31.2 |
| Capital Expenditures | -1.17 | -0.452 | -1.38 | -9.17 | -1.64 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | — | -18.9 | 2.99 | 46.5 | 14.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.17 | -19.3 | 1.61 | 37.4 | 12.5 |
| Financing Cash Flow Items | -5.11 | — | — | — | -1.06 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 64 | 0.9 | 40.4 | 3.51 | 14.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.1 | -37.5 | 3.95 | -8.07 | -3.81 |